Immunomodulation – Medxy AI

Systemic Interleukin-6 Inhibition as a Novel Approach to Reduce Diabetic Retinopathy Risk and Progression

By MedXY 08/06/2026

Systemic IL-6 inhibitors are linked to significantly reduced risks of diabetic retinopathy development, progression, and vision-threatening complications, suggesting therapeutic potential for diabetic eye disease.

Allergy & Immunology Dermatology news

Beyond Th2: Single-Dose Aletekitug Targets IL-18 to Deliver Sustained Clinical and Molecular Remission in Atopic Dermatitis

By MedXY 03/05/2026

A phase 1/2 study reveals that a single dose of aletekitug, an anti-IL-18 antibody, provides durable clinical improvement and broad molecular modulation in moderate-to-severe atopic dermatitis, targeting pathways beyond traditional Type 2 inflammation for up to 24 weeks.

Allergy & Immunology Cardiology news

Targeted HEV Modulation: A Novel Antibody-Drug Conjugate Strategy to Overcome Cardiac Allograft Rejection

By MedXY 02/28/2026

Researchers have developed a first-in-class antibody-drug conjugate targeting High Endothelial Venules via the CHST4 enzyme. This therapy promotes regulatory T cell induction and long-term heart transplant survival in murine models using significantly lower systemic drug doses.